Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Minghui Pharmaceutical (Hangzhou): Clinical Trials & FDA Approval Profile

Minghui Pharmaceutical (Hangzhou) (Global / Institutional) sponsors 18 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 15 active protocols (11 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)160 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Minghui Pharmaceutical (Hangzhou)
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)18
Active Pipeline (Recruiting Now)15 (11)
Completed vs Stopped Early3 / 0 (0.0%)
Median Closed Actual Enrollment160 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Minghui Pharmaceutical (Hangzhou)
Hospital Research SiteLocationShared Protocols
Shanghai Chest HospitalShanghai3
Guangdong Provincial People's HospitalGuangzhou2
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality2

Explore interactive annual charts and M&A subsidiary rollups in the Minghui Pharmaceutical (Hangzhou) Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI